An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early
Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind,
randomized trial with one dose of ALZ-801 compared to placebo.